Powell Goldstein LLP in Washington appointed James Remenick partner with its intellectual property and biotechnology practices.
Rubicon Genomics, of Ann Arbor, Mich., appointed Timothy Mayleben to its board.
Salix Pharmaceutical Ltd., of Raleigh, N.C., appointed William Forbes vice president, research and development and chief development officer.
Sangamo BioSciences Inc., of Richmond, Calif., appointed David Ichikawa senior vice president, business development.
Scolr Pharma Inc., of Bellevue, Wash., appointed Alan Mitchel senior vice president of business and legal affairs, and chief legal officer.
Sirtris Pharmaceuticals Inc., of Boston, appointed Michael Milburn senior vice president of research and corporate development.
Tercica Inc., of South San Francisco, appointed Thorsten von Stein chief medical officer and senior vice president, clinical and regulatory affairs.
Therion Biologics, of Cambridge, Mass., formed a clinical advisory board with Al Benson, Matthew Kulke, Howard Kaufman, John Marshall, John Nemunaitis and Daniel Von Hoff.
Vasogen Inc., of Toronto, appointed Jay Kleiman chief medical officer and head of cardiovascular development, Michael Shannon vice president of medical affairs, and Marguerite Ethier general counsel and corporate secretary.